Merryl Cramer

1.2k citations
16 papers · 846 · 1 hit paper · h-index 11

Impact in

  • Hematology top 2%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 5%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Merryl Cramer

16 papers receiving 828 citations

Hit Papers

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) 2009 · 474 citations
4740+5+11Years since publication100200300400

Peers

Merryl Cramer
Comparison fields: 5 of 64
  • Hematology 451
  • Genetics 215
  • Cellular and Molecular Neuroscience 118
  • Molecular Biology 437
  • Organic Chemistry 153
Replace Dong-Mei Feng with:
Dong-Mei Feng United States
Jack A. Kauffman United States
Erica O’Bryan United States
Christine Lambert‐van der Brempt United Kingdom
Gerard Costello United Kingdom
Da-Sheng Wang United States
Mary Adams United States
Kelli Glenn United States
John M. Hatcher United States
Itsuro Shimada Japan
Merryl Cramer relative to Dong-Mei Feng United States Dong-Mei Feng's profile →
Citations per field
00.5×10×12.8×
Dong-Mei Feng · 1×
Citations per year

Countries citing papers authored by Merryl Cramer

Since Specialization
Citations

This map shows the geographic impact of Merryl Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merryl Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merryl Cramer more than expected).

Fields of papers citing papers by Merryl Cramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Merryl Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merryl Cramer. The network helps show where Merryl Cramer may publish in the future.

Co-authors

The 25 scholars most cited alongside Merryl Cramer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Merryl Cramer Line = papers co-authored together Merryl Cramer links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Hit paper breakdown →
2009474
2 2009167
3 200441
4 200536
5 200425
6 200419
7 200414
8 201113
9 200412
10 200511
11 200510
12 200510
13 20056
14 20054
15 20053
16 20051

About Merryl Cramer

Merryl Cramer is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience, Genetics, Genetics and Oncology, having authored 16 papers that have together received 846 indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (4 papers), Genetics and Neurodevelopmental Disorders (3 papers), Acute Myeloid Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Adenosine and Purinergic Signaling (2 papers), RNA Interference and Gene Delivery (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Hematology (451 citations), Genetics (215 citations), Cellular and Molecular Neuroscience (118 citations), Molecular Biology (437 citations) and Organic Chemistry (153 citations). Merryl Cramer has collaborated with scholars based in United States. Frequent co-authors include Michael F. Gardner, Joyce James, Shripad S. Bhagwat, Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Kelly G. Sprankle, Qi Chao, Hitesh Patel, Barbara Belli and Robert C. Armstrong. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Blood, Journal of Medicinal Chemistry, Drug Metabolism and Disposition and Neuroscience Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact